Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties

PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Cao*, Liangxian, Weetall, Marla, Trotta, Christopher, Cintron, Katherine, Ma, Jiyuan, Kim, Min Jung, Furia, Bansri, Romfo, Charles, Graci, Jason D., Li, Wencheng, Du, Joshua, Sheedy, Josephine, Hedrick, Jean, Risher, Nicole, Yeh, Shirley, Qi, Hongyan, Arasu, Tamil, Hwang, Seongwoo, Lennox, William, Kong, Ronald, Petruska, Janet, Moon, Young-Choon, Babiak, John, Davis, Thomas W., Jacobson, Allan, Almstead, Neil G., Branstrom, Art, Colacino, Joseph M., Peltz, Stuart W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6318026/
https://ncbi.nlm.nih.gov/pubmed/30352802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0863
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi